Governance Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 14:57:21 13/11/2025 GMT			5-day change	1st Jan Change
126.96 ^USD	+2.89%		+1.22%	+35.22%

01:45pm	Daiwa Securities Adjusts Gilead Sciences Price Target to $129 From $128, Maintains Outperform Rating	MT
11:06am	Scotiabank Initiates Gilead Sciences at Sector Outperform With $140 Price Target	MT

Executive Committee: Gilead Sciences, Inc.

Manager

Positions heldSince

Daniel O'Day

60 year

Chief Executive Officer

28/02/2019

Dietmar Berger

Chief Tech/Sci/R&D Officer

01/01/2025

Sarah Miksinski

General Counsel

Deborah Telman

60 year

General Counsel	31/07/2022
Corporate Secretary	31/07/2022

Jacquie Ross

Investor Relations Contact

31/12/2020

Jyoti Mehra

49 year

Human Resources Officer

31/10/2017

Andrew Dickinson

55 year

Director of Finance/CFO

31/10/2019

Erin Burkhart

56 year

Comptroller/Controller/Auditor

21/09/2025

Composition of the Board of Directors: Gilead Sciences, Inc.

Director

CommitteesSince

Daniel O'Day

60 year

Chairman

28/02/2019

Kelly Kramer

57 year

Compensation Committee	30/11/2021
HR Committee
Audit Committee Chair	30/11/2020
Audit Committee	30/11/2021
Governance Committee	31/01/2020
Nominating Committee	31/01/2020

Harish M. Manwani

71 year

HR Committee	08/05/2018
Governance Committee	16/08/2011
Nominating Committee	11/05/2021
Compensation Committee	08/05/2018
Governance Committee Chair	11/05/2021

Anthony Welters

70 year

Governance Committee	11/05/2021
Nominating Committee	11/05/2021
Compensation Committee Chair	16/10/2020
HR Committee	16/10/2020

Ted Love

66 year

Governance Committee Chair
Nominating Committee Chair
Compensation Committee Chair	02/08/2023
Audit Committee	31/01/2024

Sandra Horning

76 year

Governance Committee	12/11/2020
Nominating Committee	12/11/2020

Jacqueline Barton

72 year

Compensation Committee	31/12/2017
HR Committee	31/12/2017

Javier Rodriguez

54 year

Audit Committee

14/06/2020

Jeffrey Bluestone

71 year

Executive Committee

08/04/2020

Latest Appointments: Gilead Sciences, Inc.

11-10	Nurix Therapeutics, Inc. Appoints Roger Dansey to Its Board of Directors	CI
11-07	Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors	CI
11-03	Prime Medicine, Inc. Appoints Matthew Hawryluk as Chief Business Officer	CI
10-31	Galapagos NV Announces Board Changes, Effective November 1, 2025	CI
10-28	Jazz Pharmaceuticals plc Announces Board Changes, Effective December 1, 2025	CI
08-14	Gilead Sciences, Inc. Announces Management Changes, Effective September 22, 2025	CI
06-26	Pharos Energy Names New Nonexecutive Chair	MT

More news

Former Officers and Directors: Gilead Sciences, Inc.

Insider

Positions held

SinceUntil

Kevin Lofton

Director/Board Member	28/07/2009	07/05/2024
Independent Dir/Board Member	28/07/2009	07/05/2024

Brett Pletcher

Compliance Officer	-	31/07/2022
General Counsel	30/03/2011	31/07/2022
Corporate Officer/Principal	31/12/2004	30/03/2011
Corporate Secretary	-	31/07/2022

Tai Yin Yang

Corporate Officer/Principal

31/12/2004

17/07/2022

Amy E. Flood

Public Communications Contact

31/05/2021

William Lee

Chief Tech/Sci/R&D Officer

31/12/1990

11/04/2021

Richard Whitley

Director/Board Member	30/06/2008	31/12/2020
Independent Dir/Board Member	30/06/2008	31/12/2020

Robin Washington

Comptroller/Controller/Auditor	04/05/2008	31/10/2019
Director of Finance/CFO	04/05/2008	31/10/2019

Gregg Alton

Chief Executive Officer	31/12/2018	28/02/2019
Compliance Officer	31/12/1998	-
Public Communications Contact	03/08/2009	08/05/2012
General Counsel	31/12/1998	03/08/2009
Corporate Officer/Principal	28/02/2019	03/10/2019
Corporate Secretary	31/12/1998	-

John McHutchison

Chief Tech/Sci/R&D Officer	28/02/2018	01/08/2019
Corporate Officer/Principal	07/06/2010	28/02/2018

John Martin

Chief Executive Officer	31/12/1995	09/03/2016
Chairman	31/05/2008	28/02/2019

John Milligan

Director/Board Member	27/01/2016	30/12/2018
Chief Executive Officer	09/03/2016	30/12/2018
Chief Operating Officer	31/12/2006	09/03/2016
Director of Finance/CFO	31/12/2001	31/12/2006
President	31/12/2007	30/12/2018

Andrew Cheng

Chief Tech/Sci/R&D Officer	-	06/09/2018
Corporate Officer/Principal	31/12/1998	-

Norbert W. Bischofberger

Chief Tech/Sci/R&D Officer	31/12/1994	29/04/2018
Corporate Officer/Principal	31/07/1990	31/12/1994

James Meyers

Corporate Officer/Principal

31/12/1995

21/02/2018

John Madigan

Director/Board Member	30/11/2005	09/05/2017
Independent Dir/Board Member	21/07/2011	09/05/2017

Paul Carter

Corporate Officer/Principal

31/03/2006

31/07/2016

Kevin B. Young

Corporate Officer/Principal	31/08/2004	03/02/2014
Chief Operating Officer	23/05/2016	-

Gordon Earle Moore

Director/Board Member	31/12/1995	30/05/2013
Independent Dir/Board Member	21/07/2011	30/05/2013

James M. Denny

Director/Board Member	31/12/1995	30/05/2013
Independent Dir/Board Member	21/07/2011	30/05/2013

Susan T. Hubbard

Investor Relations Contact

31/08/1989

31/05/2012

Alan Montgomery

Corporate Officer/Principal

31/07/2006

30/04/2011

Anthony D. Caracciolo

Corporate Officer/Principal

31/12/1996

30/09/2010

Per Wold-Olsen

Director/Board Member	27/01/2010	-
Independent Dir/Board Member	27/01/2010	-

Louis Lange

Corporate Officer/Principal

19/04/2009

Seigo Izumo

Corporate Officer/Principal

31/08/2008

Caroline Dorsa

Director of Finance/CFO

04/11/2007

16/01/2008

Howard Rosen

Corporate Officer/Principal

31/12/2003

31/12/2007

Carla A. Hills

Director/Board Member	31/12/2006	-
Independent Dir/Board Member	21/07/2011	-

Kristen M. Metza

Human Resources Officer

31/12/2005

Steven Fife

Comptroller/Controller/Auditor

31/12/2004

31/12/2005

John Francis Cogan

Director/Board Member	30/06/2005	-
Independent Dir/Board Member	30/06/2005	-

Nicholas G. Moore

Director/Board Member	29/02/2004	-
Independent Dir/Board Member	29/02/2004	-

Karl G. Trass

General Counsel

31/12/2002

30/06/2003

James Sapirstein

Sales & Marketing

31/05/2000

31/05/2002

Rebecca Coleman

Director/Board Member

01/01/2000

Michael W. Aguiar

Director of Finance/CFO

31/12/2001

Robert L. Simon

General Counsel

30/06/2000

30/11/2001

Gayle Edlund Wilson

Director/Board Member	30/09/2001	-
Independent Dir/Board Member	30/09/2001	-

Jeff Bird

Corporate Officer/Principal

31/12/1999

Kenneth Cundy

Corporate Officer/Principal

31/12/1991

31/12/1999

Mark D. Matteucci

Corporate Officer/Principal

31/12/1987

31/12/1998

Louis C. Bock

Corporate Officer/Principal

31/08/1989

Robert J. Stagg

Chief Tech/Sci/R&D Officer

31/07/1993

30/11/1996

Bill Harris

Director of Finance/CFO

31/12/1989

31/12/1995

Michael Bigham

Chief Operating Officer	31/12/1987	31/12/1995
Director of Finance/CFO	31/12/1987	31/12/1995

George Pratt Shultz

Director/Board Member

31/12/1995

John Latham

Corporate Officer/Principal

31/12/1988

31/12/1993

Étienne Francois Davignon

Director/Board Member	31/08/1990	-
Independent Dir/Board Member	21/07/2011	-

John J. Toole

Corporate Officer/Principal

31/03/1990

Akram Bouchenaki

Corporate Officer/Principal

Nicholas S. Hellmann

Corporate Officer/Principal

Joseph M. Baini

Corporate Officer/Principal

Wenjin Yang

Corporate Officer/Principal

James V. Desiderio

Corporate Officer/Principal

Jim Ziegler

Corporate Officer/Principal	-	-
Sales & Marketing	-	-

George Tidmarsh

Corporate Officer/Principal

Erin Edgley

Public Communications Contact

Patrick O'Brien

Investor Relations Contact

Sunil Patel

Corporate Officer/Principal

Dirk B. Mendel

Corporate Officer/Principal

Jeffrey Rudy

Corporate Officer/Principal

Gulshan H. Shaver

Corporate Officer/Principal

Gary C. Visor

Corporate Officer/Principal

Roger G. Mills

Corporate Officer/Principal

Julie Cherrington

Corporate Officer/Principal

Cordell W. Hull

Director/Board Member

David Brogan

Corporate Officer/Principal

Jeffery P. Davis

Corporate Officer/Principal

Mark Italia

General Counsel

Richard J. Gorczynski

Corporate Officer/Principal

Pamela Goss

Corporate Officer/Principal

Adam Tomasi

Corporate Officer/Principal

Robert L. St. Claire

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	19
Female	9

Of which Executive Committee

Male	4
Female	4

Of which Directors

Male	8
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Employees

17,600

Sector

Pharmaceuticals

Calendar

11-19 - Jefferies Global Healthcare Conference

More about the company